BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down? World J Gastroenterol 2006; 12(38): 6102-6108 [PMID: 17036379 DOI: 10.3748/wjg.v12.i38.6102] [Cited by in CrossRef: 278] [Cited by in F6Publishing: 259] [Article Influence: 18.5] [Reference Citation Analysis]
Number Citing Articles
1 Cheng Z, Peng H, Zhang R, Fu X, Zhang G. Bone marrow-derived innate macrophages attenuate oxazolone-induced colitis. Cellular Immunology 2017;311:46-53. [DOI: 10.1016/j.cellimm.2016.10.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
2 Tan Y, Guan Y, Sun Y, Zheng C. Correlation of Intestinal Mucosal Healing and Tight Junction Protein Expression in Ulcerative Colitis Patients. Am J Med Sci. 2019;357:195-204. [PMID: 30638599 DOI: 10.1016/j.amjms.2018.11.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
3 Rogler D, Fournier N, Pittet V, Bühr P, Heyland K, Friedt M, Koller R, Rueger V, Herzog D, Nydegger A, Schäppi M, Schibli S, Spalinger J, Rogler G, Braegger CP; Swiss IBD Cohort Study Group. Coping is excellent in Swiss Children with inflammatory bowel disease: results from the Swiss IBD cohort study. J Crohns Colitis 2014;8:409-20. [PMID: 24230970 DOI: 10.1016/j.crohns.2013.10.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
4 Man SM, Zhang L, Day AS, Leach S, Mitchell H. Detection of enterohepatic and gastric helicobacter species in fecal specimens of children with Crohn's disease. Helicobacter. 2008;13:234-238. [PMID: 18665930 DOI: 10.1111/j.1523-5378.2008.00607.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
5 Hansen TS, Jess T, Vind I, Elkjaer M, Nielsen MF, Gamborg M, Munkholm P. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohns Colitis. 2011;5:577-584. [PMID: 22115378 DOI: 10.1016/j.crohns.2011.05.010] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 8.6] [Reference Citation Analysis]
6 Inamdar S, Volfson A, Rosen L, Sunday S, Katz S, Sultan K. Smoking and Early Infliximab Response in Crohn's Disease: a Meta-analysis. Journal of Crohn's and Colitis 2015;9:140-6. [DOI: 10.1093/ecco-jcc/jju018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
7 Schoultz M, Atherton I, Hubbard G, Watson AJ. Assessment of causal link between psychological factors and symptom exacerbation in inflammatory bowel disease: a protocol for systematic review of prospective cohort studies. Syst Rev 2013;2:8. [PMID: 23343187 DOI: 10.1186/2046-4053-2-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
8 Quezada SM, Langenberg P, Cross RK. Cigarette smoking adversely affects disease activity and disease-specific quality of life in patients with Crohn's disease at a tertiary referral center. Clin Exp Gastroenterol 2016;9:307-10. [PMID: 27703391 DOI: 10.2147/CEG.S104652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
9 Forster K, Goethel A, Chan CW, Zanello G, Streutker C, Croitoru K. An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology 2012;143:1298-307. [PMID: 22819863 DOI: 10.1053/j.gastro.2012.07.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
10 Kiss LS, Lakatos PL. Prediction of the disease course in inflammatory bowel diseases. Orvosi Hetilap 2010;151:293-301. [DOI: 10.1556/oh.2010.28813] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Fatani AJ, Al-Hosaini KA, Ahmed MM, Abuohashish HM, Parmar MY, Al-Rejaie SS. Carvedilol attenuates inflammatory biomarkers and oxidative stress in a rat model of ulcerative colitis. Drug Dev Res. 2015;76:204-214. [PMID: 26109469 DOI: 10.1002/ddr.21256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
12 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990. [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 478] [Article Influence: 59.9] [Reference Citation Analysis]
13 Boal Carvalho P, Dias de Castro F, Rosa B, Moreira MJ, Cotter J. Mucosal Healing in Ulcerative Colitis--When Zero is Better. J Crohns Colitis. 2016;10:20-25. [PMID: 26438714 DOI: 10.1093/ecco-jcc/jjv180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
14 Volpato E, Bosio C, Previtali E, Leone S, Armuzzi A, Pagnini F, Graffigna G. The evolution of IBD perceived engagement and care needs across the life-cycle: a scoping review. BMC Gastroenterol 2021;21:293. [PMID: 34261434 DOI: 10.1186/s12876-021-01850-1] [Reference Citation Analysis]
15 Ooi JH, Waddell A, Lin YD, Albert I, Rust LT, Holden V, Cantorna MT. Dominant effects of the diet on the microbiome and the local and systemic immune response in mice. PLoS One. 2014;9:e86366. [PMID: 24489720 DOI: 10.1371/journal.pone.0086366] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
16 Zhu H, Lei X, Liu Q, Wang Y. Interleukin-10-1082A/G polymorphism and inflammatory bowel disease susceptibility: a meta-analysis based on 17,585 subjects. Cytokine. 2013;61:146-153. [PMID: 23046617 DOI: 10.1016/j.cyto.2012.09.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
17 Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles C, Ochs HD, Bonilla FA, Paris K, Yel L, Sullivan KE. Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol 2014;34:627-32. [PMID: 24909997 DOI: 10.1007/s10875-014-0056-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
18 Tan CX, Brand HS, de Boer NK, Forouzanfar T. Gastrointestinal diseases and their oro-dental manifestations: Part 2: Ulcerative colitis. Br Dent J. 2017;222:53-57. [PMID: 28084352 DOI: 10.1038/sj.bdj.2017.37] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
19 Baghaei A, Emami MH, Adibi P, Tavakkoli H, Daghaghzadeh H, Tamizifar B, Akbarpour MJ, Hojjatpour B. Inflammatory Bowel Disease Registry and Monitoring: Feasibility Study and Application (Isfahan Inflammatory Bowel Disease Surveillance Project). Int J Prev Med 2019;10:190. [PMID: 31807260 DOI: 10.4103/ijpvm.IJPVM_316_17] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Soletti RC, Rodrigues NA, Biasoli D, Luiz RR, de Souza HS, Borges HL. Immunohistochemical analysis of retinoblastoma and β-catenin as an assistant tool in the differential diagnosis between Crohn's disease and ulcerative colitis. PLoS One 2013;8:e70786. [PMID: 23967107 DOI: 10.1371/journal.pone.0070786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
21 Ren K, Yuan H, Zhang Y, Wei X, Wang D. Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis. Clin Immunol 2015;160:71-81. [PMID: 25869296 DOI: 10.1016/j.clim.2015.03.027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
22 Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011;17:802-808. [PMID: 20848547 DOI: 10.1002/ibd.21365] [Cited by in Crossref: 123] [Cited by in F6Publishing: 110] [Article Influence: 12.3] [Reference Citation Analysis]
23 Lim D, Cho Y, Kim W, Jeong S, Jang YP, Kim J. Original Research: Extract of Bambusae Caulis in Taeniam inhibits cigarette smoke-induced pulmonary and intestinal inflammation. Exp Biol Med (Maywood) 2017;242:102-12. [PMID: 27590499 DOI: 10.1177/1535370216664429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Perin RL, Damião AOMC, Flores C, Ludvig JC, Magro DO, Miranda EF, Moraes ACD, Nones RB, Teixeira FV, Zeroncio M, Kotze PG. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY. Arq Gastroenterol 2019;56:312-7. [DOI: 10.1590/s0004-2803.201900000-58] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Birkenfeld S, Zvidi I, Hazazi R, Niv Y. The Prevalence of Ulcerative Colitis in Israel: A Twenty-year Survey. Journal of Clinical Gastroenterology 2009;43:743-6. [DOI: 10.1097/mcg.0b013e31818b3a02] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
26 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
27 Ling XH, Yu X, Kong DJ, Hu CY, Hong Y, Yang XM. Treatment of inflammatory bowel disease with Chinese drugs administered by both oral intake and retention enema. Chin J Integr Med. 2010;16:222-228. [PMID: 20694776 DOI: 10.1007/s11655-010-0222-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
28 Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev Clin Immunol. 2013;9:65-75; quiz 76. [PMID: 23256765 DOI: 10.1586/eci.12.86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
29 Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, Alinaghi S, Shahrokh S, Asadzadeh Aghdaei H, Zali MR. Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomed Rep 2017;6:698-702. [PMID: 28584644 DOI: 10.3892/br.2017.908] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
30 Bassaganya-Riera J, Hontecillas R. Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2010;13:569-73. [PMID: 20508519 DOI: 10.1097/MCO.0b013e32833b648e] [Cited by in Crossref: 66] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
31 Rankala R, Kosonen J, Mattila K, Tuominen R, Voutilainen M, Mustonen A. Direct costs of inflammatory bowel diseases in a Finnish tertiary-level clinic. Frontline Gastroenterol 2021;12:385-9. [DOI: 10.1136/flgastro-2020-101466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Shanahan F, Bernstein CN. The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol. 2009;25:301-305. [PMID: 19349861 DOI: 10.1097/mog.0b013e32832b12ef] [Cited by in Crossref: 73] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
33 Ng SC. Changing Epidemiology and Future Challenges of Inflammatory Bowel Disease in Asia. Intest Res 2010;8:1. [DOI: 10.5217/ir.2010.8.1.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Schreiber S, Kamm MA, Lichtenstein GR. Mesalamine with MMX™ technology for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:299-314. [DOI: 10.1586/17474124.2.3.299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
35 Alhagamhmad MH, Day AS, Lemberg DA, Leach ST. An update of the role of nutritional therapy in the management of Crohn’s disease. J Gastroenterol. 2012;47:872-882. [PMID: 22699323 DOI: 10.1007/s00535-012-0617-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
36 Qin X. High incidence of inflammatory bowel disease with improved hygiene and failure to get human-like IBD in laboratory animals. World J Gastroenterol 2007; 13(23): 3271-3271 [PMID: 17589913 DOI: 10.3748/wjg.v13.i23.3271] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Kern I, Schoffer O, Kiess W, Henker J, Laaß MW, Winkler U, Quietzsch J, Wenzel O, Zurek M, Büttner K, Fischer P, de Laffolie J, Manuwald U, Stange T, Zenker R, Weidner J, Zimmer KP, Kunath H, Kugler J, Richter T, Rothe U. Incidence trends of pediatric onset inflammatory bowel disease in the years 2000-2009 in Saxony, Germany-first results of the Saxon Pediatric IBD Registry. PLoS One 2021;16:e0243774. [PMID: 33395450 DOI: 10.1371/journal.pone.0243774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Exarchos G, Gklavas A, Metaxa L, Papaconstantinou I. Quality of life of ulcerative colitis patients treated surgically with proctocolectomy and J-pouch formation: a comparative study before surgery and after closure of the defunctioning ileostomy. Ann Gastroenterol 2018;31:350-5. [PMID: 29720861 DOI: 10.20524/aog.2018.0247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Clavel T, Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm Bowel Dis. 2007;13:1153-1164. [PMID: 17476679 DOI: 10.1002/ibd.20174] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 5.4] [Reference Citation Analysis]
40 Hustinx R, Louis E. The Role of PET/CT in the Monitoring and Diagnosis of Pediatric Inflammatory Bowel Disease. PET Clinics 2008;3:597-603. [DOI: 10.1016/j.cpet.2009.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Romier B, Schneider YJ, Larondelle Y, During A. Dietary polyphenols can modulate the intestinal inflammatory response. Nutr Rev. 2009;67:363-378. [PMID: 19566597 DOI: 10.1111/j.1753-4887.2009.00210.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 146] [Article Influence: 13.1] [Reference Citation Analysis]
42 Kokoszko-bilska A, Sobkiewicz S, Fichna J. Inflammatory bowel diseases and reproductive health. Pharmacological Reports 2016;68:859-64. [DOI: 10.1016/j.pharep.2016.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
43 Maruszewska-Cheruiyot M, Donskow-Łysoniewska K, Doligalska M. Helminth Therapy: Advances in the use of Parasitic Worms Against Inflammatory Bowel Diseases and its Challenges. Helminthologia 2018;55:1-11. [PMID: 31662622 DOI: 10.1515/helm-2017-0048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
44 Iizuka M, Harada T, Yamano HO, Etou T, Sagara S. Typical gastroduodenal endoscopic findings in a Crohn's disease patient in remission stage. World J Gastrointest Endosc 2012; 4(3): 96-98 [PMID: 22442748 DOI: 10.4253/wjge.v4.i3.96] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
45 Han Y, Lin MB, He YG, Zhang HB, Zhang YJ, Yin L. Laparoscopic surgery for inflammatory bowel disease--the experience in China. J Invest Surg 2013;26:180-5. [PMID: 23514051 DOI: 10.3109/08941939.2012.732664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Trivedi I, Keefer L. The Emerging Adult with Inflammatory Bowel Disease: Challenges and Recommendations for the Adult Gastroenterologist. Gastroenterol Res Pract. 2015;2015:260807. [PMID: 26064089 DOI: 10.1155/2015/260807] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
47 Boeing H, Bechthold A, Bub A, Ellinger S, Haller D, Kroke A, Leschik-Bonnet E, Müller MJ, Oberritter H, Schulze M, Stehle P, Watzl B. Critical review: vegetables and fruit in the prevention of chronic diseases. Eur J Nutr 2012;51:637-63. [PMID: 22684631 DOI: 10.1007/s00394-012-0380-y] [Cited by in Crossref: 935] [Cited by in F6Publishing: 737] [Article Influence: 103.9] [Reference Citation Analysis]
48 Varma S, Bird R, Eskin M, Dolenko B, Raju J, Bezabeh T. Detection of inflammatory bowel disease by proton magnetic resonance spectroscopy (1H MRS) using an animal model. J Inflamm (Lond). 2007;4:24. [PMID: 18039383 DOI: 10.1186/1476-9255-4-24] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
49 Papada E, Kaliora AC, Gioxari A, Papalois A, Forbes A. Anti-inflammatory effect of elemental diets with different fat composition in experimental colitis. Br J Nutr 2014;111:1213-20. [DOI: 10.1017/s0007114513003632] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
50 Ikhtaire S, Shajib MS, Reinisch W, Khan WI. Fecal calprotectin: Its scope and utility in the management of inflammatory bowel disease. J Gastroenterol. 2016;51:434-446. [PMID: 26897740 DOI: 10.1007/s00535-016-1182-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
51 Green C, Bernstein CN. Lessons from geographic mapping of IBD in France: . Inflammatory Bowel Diseases 2010;16:804-6. [DOI: 10.1002/ibd.21115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Kuchler U, Luvizuto ER, Muñoz F, Hofbauer J, Watzek G, Gruber R. Bone healing around titanium implants in two rat colitis models. Clin Oral Implants Res 2013;24:224-9. [PMID: 22509782 DOI: 10.1111/j.1600-0501.2012.02454.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
54 Bellizzi A, Barucca V, Fioriti D, Colosimo MT, Mischitelli M, Anzivino E, Chiarini F, Pietropaolo V. Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation. J Cell Physiol 2010;224:316-26. [DOI: 10.1002/jcp.22146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
55 Gao Y, Huang Y, Zhao Y, Hu Y, Li Z, Guo Q, Zhao K, Lu N. LL202 protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting MAPK/AP-1 signaling. Oncotarget 2016;7:63981-94. [PMID: 27590510 DOI: 10.18632/oncotarget.11742] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
56 Dupont B, Dupont C, Justum A, Piquet M, Reimund J. Enteral nutrition in adult Crohn's disease: Present status and perspectives. Mol Nutr Food Res 2008;52:875-84. [DOI: 10.1002/mnfr.200800093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kong SW, Lee IH, Leshchiner I, Krier J, Kraft P, Rehm HL, Green RC, Kohane IS, MacRae CA; MedSeq Project. Summarizing polygenic risks for complex diseases in a clinical whole-genome report. Genet Med 2015;17:536-44. [PMID: 25341114 DOI: 10.1038/gim.2014.143] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
58 Lovasz BD, Golovics PA, Vegh Z, Lakatos PL. New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe. Dig Liver Dis. 2013;45:269-276. [PMID: 23010518 DOI: 10.1016/j.dld.2012.08.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
59 Goodhand J, Hedin CR, Croft NM, Lindsay JO. Adolescents with IBD: the importance of structured transition care. J Crohns Colitis. 2011;5:509-519. [PMID: 22115368 DOI: 10.1016/j.crohns.2011.03.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 6.9] [Reference Citation Analysis]
60 Lakatos PL, Lakatos L. Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis. Orvosi Hetilap 2009;150:397-404. [DOI: 10.1556/oh.2009.28555] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Goel R, Hardman J, Gulati M, O'Donohue J. Video capsule retention in inflammatory bowel disease: an unusual presentation and discussion of retrieval methods. Case Rep Gastrointest Med 2013;2013:607142. [PMID: 23533843 DOI: 10.1155/2013/607142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
62 Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith KG. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011;121:4170-9. [PMID: 21946256 DOI: 10.1172/JCI59255] [Cited by in Crossref: 179] [Cited by in F6Publishing: 89] [Article Influence: 17.9] [Reference Citation Analysis]
63 Seibel J, Molzberger AF, Hertrampf T, Laudenbach-Leschowski U, Diel P. Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. Eur J Nutr. 2009;48:213-220. [PMID: 19234664 DOI: 10.1007/s00394-009-0004-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 5.9] [Reference Citation Analysis]
64 Lewis SN, Garcia Z, Hontecillas R, Bassaganya-Riera J, Bevan DR. Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands. J Comput Aided Mol Des 2015;29:421-39. [PMID: 25616366 DOI: 10.1007/s10822-015-9831-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
65 Chen Y, Noble EG. Is exercise beneficial to the inflammatory bowel diseases? An implication of heat shock proteins. Med Hypotheses 2009;72:84-6. [PMID: 18829174 DOI: 10.1016/j.mehy.2008.06.045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
66 Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, Foldi I, Lakos G, Tumpek J, Udvardy ML. Seroreactivity to microbial components in Crohn’s disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis. 2007;13:984-992. [PMID: 17417801 DOI: 10.1002/ibd.20146] [Cited by in Crossref: 53] [Cited by in F6Publishing: 61] [Article Influence: 3.8] [Reference Citation Analysis]
67 Pitari GM. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis. Drug Des Devel Ther 2013;7:351-60. [PMID: 23637522 DOI: 10.2147/DDDT.S32252] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
68 Meroni E, Stakenborg N, Gomez-Pinilla PJ, De Hertogh G, Goverse G, Matteoli G, Verheijden S, Boeckxstaens GE. Functional characterization of oxazolone-induced colitis and survival improvement by vagus nerve stimulation. PLoS One 2018;13:e0197487. [PMID: 29791477 DOI: 10.1371/journal.pone.0197487] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
69 Rana SS, Sharma V, Sharma R, Nada R, Gupta R, Bhasin DK. Capsule endoscopy in small bowel Crohn’s disease and Tuberculosis. Trop Doct 2017;47:113-8. [DOI: 10.1177/0049475516686542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167-3182. [PMID: 19086963 DOI: 10.1111/j.1572-0241.2008.02158.x] [Cited by in Crossref: 337] [Cited by in F6Publishing: 339] [Article Influence: 28.1] [Reference Citation Analysis]
71 Goodhand JR, Kamperidis N, Joshi NM, Wahed M, Koodun Y, Cantor EJ, Croft NM, Langmead FL, Lindsay JO, Rampton DS. The phenotype and course of inflammatory bowel disease in UK patients of Bangladeshi descent. Aliment Pharmacol Ther. 2012;35:929-940. [PMID: 22404452 DOI: 10.1111/j.1365-2036.2012.05043.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
72 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
73 Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O, Høie O, Rydning A, Vatn MH. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol. 2011;46:1081-1091. [PMID: 21619483 DOI: 10.3109/00365521.2011.584897] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 8.0] [Reference Citation Analysis]
74 Abreu-Delgado Y, Isidro RA, Torres EA, González A, Cruz ML, Isidro AA, González-Keelan CI, Medero P, Appleyard CB. Serum vitamin D and colonic vitamin D receptor in inflammatory bowel disease. World J Gastroenterol 2016; 22(13): 3581-3591 [PMID: 27053850 DOI: 10.3748/wjg.v22.i13.3581] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
75 Gioxari A, Kaliora AC, Papalois A, Agrogiannis G, Triantafillidis JK, Andrikopoulos NK. Pistacia lentiscus resin regulates intestinal damage and inflammation in trinitrobenzene sulfonic acid-induced colitis. J Med Food 2011;14:1403-11. [PMID: 21612460 DOI: 10.1089/jmf.2010.0240] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
76 Zheng B, Morgan ME, van de Kant HJ, Garssen J, Folkerts G, Kraneveld AD. Transcriptional modulation of pattern recognition receptors in acute colitis in mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2013;1832:2162-72. [DOI: 10.1016/j.bbadis.2013.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
77 Lakatos PL, Kiss LS, Palatka K, Altorjay I, Antal-Szalmas P, Palyu E, Udvardy M, Molnar T, Farkas K, Veres G, Harsfalvi J, Papp J, Papp M. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis. 2011;17:767-777. [PMID: 20865702 DOI: 10.1002/ibd.21402] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
78 Zvidi I, Hazazi R, Birkenfeld S, Niv Y. The prevalence of Crohn’s disease in Israel: a 20-year survey. Dig Dis Sci. 2009;54:848-852. [PMID: 18649132 DOI: 10.1007/s10620-008-0429-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
79 Lau KS, Juchheim AM, Cavaliere KR, Philips SR, Lauffenburger DA, Haigis KM. In vivo systems analysis identifies spatial and temporal aspects of the modulation of TNF-α-induced apoptosis and proliferation by MAPKs. Sci Signal 2011;4:ra16. [PMID: 21427409 DOI: 10.1126/scisignal.2001338] [Cited by in Crossref: 54] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
80 Jhundoo HD, Siefen T, Liang A, Schmidt C, Lokhnauth J, Béduneau A, Pellequer Y, Larsen CC, Lamprecht A. Anti-Inflammatory Activity of Chitosan and 5-Amino Salicylic Acid Combinations in Experimental Colitis. Pharmaceutics 2020;12:E1038. [PMID: 33138176 DOI: 10.3390/pharmaceutics12111038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
81 M'Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013;6:33-47. [PMID: 24833941 DOI: 10.4137/cgast.s12731] [Cited by in Crossref: 120] [Cited by in F6Publishing: 80] [Article Influence: 15.0] [Reference Citation Analysis]
82 Ye JH, Rajendran VM. Adenosine: An immune modulator of inflammatory bowel diseases. World J Gastroenterol 2009; 15(36): 4491-4498 [PMID: 19777607 DOI: 10.3748/wjg.15.4491] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
83 Parra RS, Chebli JM, Amarante HM, Flores C, Parente JM, Ramos O, Fernandes M, Rocha JJ, Feitosa MR, Feres O, Scotton AS, Nones RB, Lima MM, Zaltman C, Goncalves CD, Guimaraes IM, Santana GO, Sassaki LY, Hossne RS, Bafutto M, Junior RL, Faria MA, Miszputen SJ, Gomes TN, Catapani WR, Faria AA, Souza SC, Caratin RF, Senra JT, Ferrari ML. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J Gastroenterol 2019; 25(38): 5862-5882 [PMID: 31636478 DOI: 10.3748/wjg.v25.i38.5862] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
84 Christophorou D, Funakoshi N, Duny Y, Valats J, Bismuth M, Pineton De Chambrun G, Daures J, Blanc P. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther 2015;41:603-12. [DOI: 10.1111/apt.13102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
85 Yang LP, Mccormack PL. MMX® Mesalazine: A Review of its Use in the Management of Mild to Moderate Ulcerative Colitis. Drugs 2011;71:221-35. [DOI: 10.2165/11205870-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
86 Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Kiss LS, Lakatos L. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis 2011;5:5-13. [PMID: 21272797 DOI: 10.1016/j.crohns.2010.08.004] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 8.6] [Reference Citation Analysis]
87 Greenson JK, Odze RD. Inflammatory Disorders of the Large Intestine. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier; 2009. pp. 355-94. [DOI: 10.1016/b978-141604059-0.50017-5] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
88 Kocsis D, Tóth Z, Csontos ÁA, Miheller P, Pák P, Herszényi L, Tóth M, Tulassay Z, Juhász M. Prevalence of inflammatory bowel disease among coeliac disease patients in a Hungarian coeliac centre. BMC Gastroenterol 2015;15:141. [PMID: 26481725 DOI: 10.1186/s12876-015-0370-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
89 Wohlgemuth S, Haller D, Blaut M, Loh G. Reduced microbial diversity and high numbers of one single Escherichia coli strain in the intestine of colitic mice. Environ Microbiol 2009;11:1562-71. [PMID: 19245530 DOI: 10.1111/j.1462-2920.2009.01883.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
90 Allais L, Kerckhof FM, Verschuere S, Bracke KR, De Smet R, Laukens D, Van den Abbeele P, De Vos M, Boon N, Brusselle GG, Cuvelier CA, Van de Wiele T. Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. Environ Microbiol 2016;18:1352-63. [PMID: 26033517 DOI: 10.1111/1462-2920.12934] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 12.7] [Reference Citation Analysis]
91 Colonnello V, Agostini A. Disease course, stress, attachment, and mentalization in patients with inflammatory bowel disease. Med Hypotheses 2020;140:109665. [PMID: 32155541 DOI: 10.1016/j.mehy.2020.109665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
92 Studd C, Cameron G, Beswick L, Knight R, Hair C, McNeil J, Desmond P, Wilson J, Connell W, Bell S. Never underestimate inflammatory bowel disease: High prevalence rates and confirmation of high incidence rates in Australia. J Gastroenterol Hepatol. 2016;31:81-86. [PMID: 26222770 DOI: 10.1111/jgh.13050] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
93 Chu HP, Logarajah V, Tan N, Phua KB. Paediatric inflammatory bowel disease in a multiracial Asian country. Singapore Med J. 2013;54:201-205. [PMID: 23624446 DOI: 10.11622/smedj.2013073] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
94 Lakatos PL, Lakatos L. Ulcerative proctitis: a review of pharmacotherapy and management. Expert Opin Pharmacother. 2008;9:741-749. [PMID: 18345952 DOI: 10.1517/14656566.9.5.741] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
95 Ng SC. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol. 2014;28:363-372. [PMID: 24913377 DOI: 10.1016/j.bpg.2014.04.003] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 12.1] [Reference Citation Analysis]
96 Armstrong CM, Billimek AR, Allred KF, Sturino JM, Weeks BR, Allred CD. A novel shift in estrogen receptor expression occurs as estradiol suppresses inflammation-associated colon tumor formation. Endocr Relat Cancer 2013;20:515-25. [PMID: 23702470 DOI: 10.1530/ERC-12-0308] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
97 Byelinska I, Kuznietsova H, Dziubenko N, Lynchak O, Rybalchenko T, Prylutskyy Y, Kyzyma O, Ivankov O, Rybalchenko V, Ritter U. Effect of С60 fullerenes on the intensity of colon damage and hematological signs of ulcerative colitis in rats. Materials Science and Engineering: C 2018;93:505-17. [DOI: 10.1016/j.msec.2018.08.033] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
98 Asakura H, Suzuki K, Honma T. Recent advances in basic and clinical aspects of inflammatory bowel disease: Which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease? World J Gastroenterol 2007; 13(15): 2145-2149 [PMID: 17465491 DOI: 10.3748/wjg.v13.i15.2145] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
99 Barello S, Guida E, Leone S, Previtali E, Graffigna G. Does patient engagement affect IBD patients' health-related quality of life? Findings from a cross-sectional study among people with inflammatory bowel diseases. Health Qual Life Outcomes 2021;19:77. [PMID: 33678181 DOI: 10.1186/s12955-021-01724-w] [Reference Citation Analysis]
100 Lv H, Jiang Y, Li J, Zhang M, Shang Z, Zheng J, Wu X, Liu P, Zhang R, Yu H. Association between polymorphisms in the promoter region of interleukin-10 and susceptibility to inflammatory bowel disease. Mol Biol Rep 2014;41:1299-310. [PMID: 24407599 DOI: 10.1007/s11033-013-2975-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
101 Dobie R, MacRae VE, Pass C, Milne EM, Ahmed SF, Farquharson C. Suppressor of cytokine signaling 2 (Socs2) deletion protects bone health of mice with DSS-induced inflammatory bowel disease. Dis Model Mech 2018;11:dmm028456. [PMID: 29343614 DOI: 10.1242/dmm.028456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
102 Wang X, Sun Y, Zhao Y, Ding Y, Zhang X, Kong L, Li Z, Guo Q, Zhao L. Oroxyloside prevents dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB pathway through PPARγ activation. Biochem Pharmacol 2016;106:70-81. [PMID: 26947454 DOI: 10.1016/j.bcp.2016.02.019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
103 Sodagari HR, Farzaei MH, Bahramsoltani R, Abdolghaffari AH, Mahmoudi M, Rezaei N. Dietary anthocyanins as a complementary medicinal approach for management of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:807-20. [PMID: 25586636 DOI: 10.1586/17474124.2015.1002086] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
104 Murphy B, Kavanagh DO, Winter DC. Modern surgery for ulcerative colitis. Updates Surg 2020;72:325-33. [DOI: 10.1007/s13304-020-00719-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
105 Majewski S, Piotrowski W. Pulmonary manifestations of inflammatory bowel disease. Arch Med Sci. 2015;11:1179-1188. [PMID: 26788078 DOI: 10.5114/aoms.2015.56343] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
106 Schoultz M, Macaden L, Hubbard G. Participants' perspectives on mindfulness-based cognitive therapy for inflammatory bowel disease: a qualitative study nested within a pilot randomised controlled trial. Pilot Feasibility Stud 2016;2:3. [PMID: 27965824 DOI: 10.1186/s40814-015-0041-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
107 Li MY, Zhang ZH, Wang Z, Zuo HX, Wang JY, Xing Y, Jin CH, Xu GH, Piao LX, Ma J, Jin X. Convallatoxin protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB signaling through activation of PPARγ. Pharmacological Research 2019;147:104355. [DOI: 10.1016/j.phrs.2019.104355] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
108 Sonnenberg A. Demographic Characteristics of Hospitalized IBD Patients. Dig Dis Sci 2009;54:2449-55. [DOI: 10.1007/s10620-009-0973-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
109 Afzali A, Cross RK. Racial and Ethnic Minorities with Inflammatory Bowel Disease in the United States: A Systematic Review of Disease Characteristics and Differences. Inflamm Bowel Dis 2016;22:2023-40. [PMID: 27379446 DOI: 10.1097/MIB.0000000000000835] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 13.3] [Reference Citation Analysis]
110 Ranganathan P, Jayakumar C, Li DY, Ramesh G. UNC5B receptor deletion exacerbates DSS-induced colitis in mice by increasing epithelial cell apoptosis. J Cell Mol Med 2014;18:1290-9. [PMID: 24720832 DOI: 10.1111/jcmm.12280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
111 Kondamudi PK, Malayandi R, Eaga C, Aggarwal D. Drugs as causative agents and therapeutic agents in inflammatory bowel disease. Acta Pharmaceutica Sinica B 2013;3:289-96. [DOI: 10.1016/j.apsb.2013.06.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
112 Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012;59:118-140. [PMID: 22387836 DOI: 10.4166/kjg.2012.59.2.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
113 Lakatos PL, Czegledi Z, David G, Kispal Z, Kiss LS, Palatka K, Kristof T, Nagy F, Salamon A, Demeter P. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. J Crohns Colitis. 2010;4:283-290. [PMID: 21122517 DOI: 10.1016/j.crohns.2009.11.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
114 Yang H, Li Y, Wu W, Sun Q, Zhang Y, Zhao W, Lv H, Xia Q, Hu P, Li H, Qian J. The incidence of inflammatory bowel disease in Northern China: a prospective population-based study. PLoS One. 2014;9:e101296. [PMID: 25029440 DOI: 10.1371/journal.pone.0101296] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
115 Roberts CL, Rushworth SL, Richman E, Rhodes JM. Hypothesis: Increased consumption of emulsifiers as an explanation for the rising incidence of Crohn’s disease. J Crohns Colitis. 2013;7:338-341. [PMID: 23360575 DOI: 10.1016/j.crohns.2013.01.004] [Cited by in Crossref: 78] [Cited by in F6Publishing: 64] [Article Influence: 9.8] [Reference Citation Analysis]
116 Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: Good, bad or ugly? World J Gastroenterol 2007; 13(46): 6134-6139 [PMID: 18069751 DOI: 10.3748/wjg.v13.i46.6134] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 65] [Article Influence: 3.9] [Reference Citation Analysis]
117 Hayek AJ, Pfanner TP, White HD. Inflammatory bowel disease of the lung: The role of infliximab? Respir Med Case Rep 2015;15:85-8. [PMID: 26236612 DOI: 10.1016/j.rmcr.2015.05.012] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
118 Tsang SW, Ip SP, Wu JC, Ng SC, Yung KK, Bian ZX. A Chinese medicinal formulation ameliorates dextran sulfate sodium-induced experimental colitis by suppressing the activity of nuclear factor-kappaB signaling. J Ethnopharmacol. 2015;162:20-30. [PMID: 25554639 DOI: 10.1016/j.jep.2014.12.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
119 Li Y, de Haar C, Peppelenbosch MP, van der Woude CJ. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. Cytokine Growth Factor Rev 2012;23:127-38. [PMID: 22591635 DOI: 10.1016/j.cytogfr.2012.04.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
120 Gong Y, Li H, Li Y. Effects of Bacillus subtilis on Epithelial Tight Junctions of Mice with Inflammatory Bowel Disease. J Interferon Cytokine Res. 2016;36:75-85. [PMID: 26720180 DOI: 10.1089/jir.2015.0030] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
121 Yunusi K, Zhang J, Zhong L, Mosha G, Nuermaimaiti A, Abudula M, Upur H. Uygur medicine Xipayi Kui Jie'an affects gene expression profiles in intestinal tissue lesions in a rat model of ulcerative colitis. BMC Complement Altern Med. 2015;15:152. [PMID: 25997744 DOI: 10.1186/s12906-015-0672-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
122 Torres EA, Cruz A, Monagas M, Bernal M, Correa Y, Cordero R, Carlo VL. Inflammatory Bowel Disease in Hispanics: The University of Puerto Rico IBD Registry. Int J Inflam 2012;2012:574079. [PMID: 22195289 DOI: 10.1155/2012/574079] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
123 Amerikanou C, Dimitropoulou E, Gioxari A, Papada E, Tanaini A, Fotakis C, Zoumpoulakis P, Kaliora AC. Linking the IL-17A immune response with NMR-based faecal metabolic profile in IBD patients treated with Mastiha. Biomed Pharmacother 2021;138:111535. [PMID: 34311533 DOI: 10.1016/j.biopha.2021.111535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Reynolds CM, Loscher CE, Moloney AP, Roche HM. Cis -9, trans -11-conjugated linoleic acid but not its precursor trans -vaccenic acid attenuate inflammatory markers in the human colonic epithelial cell line Caco-2. Br J Nutr 2008;100:13-7. [DOI: 10.1017/s0007114508894329] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
125 Kuznietsova HM, Yena MS, Kotlyar IP, Ogloblya OV, Rybalchenko VK. Anti-Inflammatory Effects of Protein Kinase Inhibitor Pyrrol Derivate. ScientificWorldJournal 2016;2016:2145753. [PMID: 28101521 DOI: 10.1155/2016/2145753] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
126 Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther 2007;25:1373-88. [PMID: 17539977 DOI: 10.1111/j.1365-2036.2007.03332.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 65] [Article Influence: 5.7] [Reference Citation Analysis]
127 Seibel J, Molzberger AF, Hertrampf T, Laudenbach-Leschowski U, Degen GH, Diel P. In utero and postnatal exposure to a phytoestrogen-enriched diet increases parameters of acute inflammation in a rat model of TNBS-induced colitis. Arch Toxicol. 2008;82:941-950. [PMID: 18504553 DOI: 10.1007/s00204-008-0309-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
128 Cruz-Lebrón A, D'argenio Garcia L, Talla A, Joussef-Piña S, Quiñones-Mateu ME, Sékaly RP, de Carvalho KIL, Levine AD. Decreased Enteric Bacterial Composition and Diversity in South American Crohn's Disease Vary With the Choice of Treatment Strategy and Time Since Diagnosis. J Crohns Colitis 2020;14:791-800. [PMID: 31758685 DOI: 10.1093/ecco-jcc/jjz189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
129 Baudet A, Rahmi G, Bretagne AL, Gloro R, Justum AM, Reimund JM. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother. 2008;9:447-457. [PMID: 18220494 DOI: 10.1517/14656566.9.3.447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
130 Haller D, Antoine JM, Bengmark S, Enck P, Rijkers GT, Lenoir-Wijnkoop I. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J Nutr. 2010;140:690S-697S. [PMID: 20107148 DOI: 10.3945/jn.109.113746] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
131 Chen Y, Zhang M, Ren F. A Role of Exopolysaccharide Produced by Streptococcus thermophilus in the Intestinal Inflammation and Mucosal Barrier in Caco-2 Monolayer and Dextran Sulphate Sodium-Induced Experimental Murine Colitis. Molecules. 2019;24:pii: E513. [PMID: 30708992 DOI: 10.3390/molecules24030513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
132 Hauer-Jensen M, Denham JW, Andreyev HJ. Radiation enteropathy--pathogenesis, treatment and prevention. Nat Rev Gastroenterol Hepatol. 2014;11:470-479. [PMID: 24686268 DOI: 10.1038/nrgastro.2014.46] [Cited by in Crossref: 163] [Cited by in F6Publishing: 147] [Article Influence: 23.3] [Reference Citation Analysis]
133 Woźniak M, Barańska M, Małecka-Panas E, Talar-Wojnarowska R. The prevalence, characteristics, and determinants of anaemia in newly diagnosed patients with inflammatory bowel disease. Prz Gastroenterol 2019;14:39-47. [PMID: 30944676 DOI: 10.5114/pg.2019.83424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Bellolio Roth F, Gómez J, Cerda J. Increase in Hospital Discharges for Inflammatory Bowel Diseases in Chile Between 2001 and 2012. Dig Dis Sci 2017;62:2311-7. [PMID: 28667431 DOI: 10.1007/s10620-017-4660-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
135 Szilagyi A, Xue X. Comparison of geographic distributions of Irritable Bowel Syndrome with Inflammatory Bowel Disease fail to support common evolutionary roots: Irritable Bowel Syndrome and Inflammatory Bowel Diseases are not related by evolution. Med Hypotheses 2018;110:31-7. [PMID: 29317064 DOI: 10.1016/j.mehy.2017.10.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
136 Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol 2010; 16(21): 2591-2599 [PMID: 20518079 DOI: 10.3748/wjg.v16.i21.2591] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
137 Alegbeleye BJ. Crohn's disease in a developing African mission hospital: a case report. J Med Case Rep. 2019;13:80. [PMID: 30846003 DOI: 10.1186/s13256-019-1971-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Malíčková K, Duricová D, Bortlík M, Hrušková Z, Svobodová B, Machková N, Komárek V, Fučíková T, Janatková I, Zima T, Lukáš M. Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases. Autoimmune Dis 2011;2011:945861. [PMID: 21687600 DOI: 10.4061/2011/945861] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
139 Zhang Z, Kennedy H. Ulcerative colitis: current medical therapy and strategies for improving medication adherence. Eur J Gastroenterol Hepatol. 2009;21:1-8. [PMID: 19011573 DOI: 10.1097/MEG.0b013e32830bfb88] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
140 Choi CH, Kim Y, Kim YS, Ye BD, Lee KM, Lee BI, Jung S, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the Management of Ulcerative Colitis. Intest Res 2012;10:1. [DOI: 10.5217/ir.2012.10.1.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
141 Bączyk G, Formanowicz D, Gmerek Ł, Krokowicz P. Health-related quality of life assessment among patients with inflammatory bowel diseases after surgery - review. Prz Gastroenterol 2017;12:6-16. [PMID: 28337230 DOI: 10.5114/pg.2016.64037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
142 Andersen V, Olsen A, Carbonnel F, Tjønneland A, Vogel U. Diet and risk of inflammatory bowel disease. Dig Liver Dis. 2012;44:185-194. [PMID: 22055893 DOI: 10.1016/j.dld.2011.10.001] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
143 Olia A, Shimokawa C, Imai T, Suzue K, Hisaeda H. Suppression of systemic lupus erythematosus in NZBWF1 mice infected with Hymenolepis microstoma. Parasitol Int 2020;76:102057. [PMID: 31954872 DOI: 10.1016/j.parint.2020.102057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
144 Cantó E, Zamora C, Garcia-Planella E, Gordillo J, Ortiz MA, Perea L, Vidal S. Bacteria-related Events and the Immunological Response of Onset and Relapse Adult Crohn's Disease Patients. J Crohns Colitis 2019;13:92-9. [PMID: 30247652 DOI: 10.1093/ecco-jcc/jjy138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
145 Lachaine J, Yen L, Beauchemin C, Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol 2013;13:23. [PMID: 23363459 DOI: 10.1186/1471-230X-13-23] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
146 Lakatos PL. Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun? World J Gastroenterol 2009; 15(15): 1799-1804 [PMID: 19370774 DOI: 10.3748/wjg.15.1799] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
147 Momotani E, Romona NM, Yoshihara K, Momotani Y, Hori M, Ozaki H, Eda S, Ikegami M. Molecular pathogenesis of bovine paratuberculosis and human inflammatory bowel diseases. Vet Immunol Immunopathol. 2012;148:55-68. [PMID: 22486997 DOI: 10.1016/j.vetimm.2012.03.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
148 . Intestinal tuberculosis and schistosomiasis presenting like Crohn's disease. Internal Medicine Journal 2009;39:e13-5. [DOI: 10.1111/j.1445-5994.2009.02099.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
149 Sharifi A, Vahedi H, Nedjat S, Rafiei H, Hosseinzadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial. APMIS 2019;127:681-7. [PMID: 31274211 DOI: 10.1111/apm.12982] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 22.5] [Reference Citation Analysis]
150 Alireza Taghavi S, Reza Safarpour A, Hosseini SV, Noroozi H, Safarpour M, Rahimikazerooni S. Epidemiology of Inflammatory Bowel Diseases (IBD) in Iran: A Review of 740 Patients in Fars Province, Southern Iran. Ann Colorectal Res 2013;1:17-22. [DOI: 10.17795/acr-11477] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
151 Parmar AS, Lappalainen M, Paavola-sakki P, Halme L, Färkkilä M, Turunen U, Kontula K, Aromaa A, Salomaa V, Peltonen L, Halfvarson J, Törkvist L, D'amato M, Saavalainen P, Einarsdottir E. Association of celiac disease genes with inflammatory bowel disease in Finnish and Swedish patients. Genes Immun 2012;13:474-80. [DOI: 10.1038/gene.2012.21] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
152 Song Y, Zheng P. Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials. Journal of Food and Drug Analysis 2015;23:1-10. [DOI: 10.1016/j.jfda.2014.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
153 Lovasz BD, Lakatos L, Horvath A, Szita I, Pandur T, Mandel M, Vegh Z, Golovics PA, Mester G, Balogh M, Molnar C, Komaromi E, Kiss LS, Lakatos PL. Evolution of disease phenotype in adult and pediatric onset Crohn’s disease in a population-based cohort. World J Gastroenterol 2013; 19(14): 2217-2226 [PMID: 23599648 DOI: 10.3748/wjg.v19.i14.2217] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
154 Kaniewska M, Moniuszko A, Rydzewska G. The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis. Prz Gastroenterol 2017;12:169-74. [PMID: 29123576 DOI: 10.5114/pg.2017.70468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
155 Pulimood AB, Amarapurkar DN, Ghoshal U, Phillip M, Pai CG, Reddy DN, Nagi B, Ramakrishna BS. Differentiation of Crohn’s disease from intestinal tuberculosis in India in 2010. World J Gastroenterol 2011; 17(4): 433-443 [PMID: 21274372 DOI: 10.3748/wjg.v17.i4.433] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 70] [Article Influence: 8.0] [Reference Citation Analysis]
156 Hosseini-Carroll P, Mutyala M, Seth A, Nageeb S, Soliman D, Boktor M, Sheth A, Chapman J, Morris J, Jordan P, Manas K, Becker F, Alexander JS. Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management. World J Gastrointest Pharmacol Ther 2015; 6(4): 156-171 [PMID: 26558150 DOI: 10.4292/wjgpt.v6.i4.156] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
157 Vegh Z, Burisch J, Pedersen N, Kaimakliotis I, Duricova D, Bortlik M, Avnstrøm S, Vinding KK, Olsen J, Nielsen KR. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. J Crohns Colitis. 2014;8:1506-1515. [PMID: 24998983 DOI: 10.1016/j.crohns.2014.06.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
158 Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 6-21 [PMID: 24415853 DOI: 10.3748/wjg.v20.i1.6] [Cited by in CrossRef: 269] [Cited by in F6Publishing: 252] [Article Influence: 38.4] [Reference Citation Analysis]
159 Salva KA, Stenstrom M, Breadon JY, Odland PB, Bennett D, Longley J, Wood GS. Possible association of cutaneous Rosai-Dorfman disease and chronic Crohn disease: a case series report. JAMA Dermatol 2014;150:177-81. [PMID: 24305684 DOI: 10.1001/jamadermatol.2013.7609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
160 Lakatos PL, Lovasz BD, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Golovics PA, Vegh Z, Mandel M, Horvath A, Szathmari M, Kiss LS, Lakatos L. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis 2013;7:385-91. [PMID: 22766526 DOI: 10.1016/j.crohns.2012.06.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
161 Sonnenberg A. Hospitalization for inflammatory bowel disease in the United States between 1970 and 2004. J Clin Gastroenterol. 2009;43:297-300. [PMID: 18936713 DOI: 10.1097/mcg.0b013e31816244a0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
162 Underner M, Perriot J, Cosnes J, Beau P, Peiffer G, Meurice J. Tabagisme, sevrage tabagique et maladie de Crohn. La Presse Médicale 2016;45:390-402. [DOI: 10.1016/j.lpm.2016.02.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
163 Cooper WO, Cheetham TC, Li DK, Stein CM, Callahan ST, Morgan TM, Shintani AK, Chen N, Griffin MR, Ray WA. Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy. Arthritis Rheumatol 2014;66:444-50. [PMID: 24504818 DOI: 10.1002/art.38262] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
164 Silva BCD, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol 2014; 20(28): 9458-9467 [PMID: 25071340 DOI: 10.3748/wjg.v20.i28.9458] [Cited by in CrossRef: 116] [Cited by in F6Publishing: 91] [Article Influence: 16.6] [Reference Citation Analysis]
165 Momotani E, Ozaki H, Hori M, Yamamoto S, Kuribayashi T, Eda S, Ikegami M. Mycobacterium avium subsp. paratuberculosis lipophilic antigen causes Crohn's disease-type necrotizing colitis in Mice. Springerplus 2012;1:47. [PMID: 23519342 DOI: 10.1186/2193-1801-1-47] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
166 Catalan-serra I, Sandvik AK, Bruland T, Andreu-ballester JC. Gammadelta T Cells in Crohn’s Disease: A New Player in the Disease Pathogenesis? Journal of Crohn's and Colitis 2017;11:1135-45. [DOI: 10.1093/ecco-jcc/jjx039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
167 Weisser SB, Brugger HK, Voglmaier NS, McLarren KW, van Rooijen N, Sly LM. SHIP-deficient, alternatively activated macrophages protect mice during DSS-induced colitis. J Leukoc Biol 2011;90:483-92. [PMID: 21685246 DOI: 10.1189/jlb.0311124] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 6.3] [Reference Citation Analysis]
168 Van De Walle J, Romier B, Larondelle Y, Schneider YJ. Influence of deoxynivalenol on NF-kappaB activation and IL-8 secretion in human intestinal Caco-2 cells. Toxicol Lett. 2008;177:205-214. [PMID: 18343055 DOI: 10.1016/j.toxlet.2008.01.018] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.0] [Reference Citation Analysis]
169 Roberts MH, Erdei E. Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race. Autoimmun Rev 2020;19:102423. [PMID: 31733367 DOI: 10.1016/j.autrev.2019.102423] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
170 Gálvez J, Camuesco D, Rodríguez-cabezas ME, Zarzuelo A. Intestinal Anti-inflammatory Activity of Dietary Olive Oil. Olives and Olive Oil in Health and Disease Prevention. Elsevier; 2010. pp. 1049-55. [DOI: 10.1016/b978-0-12-374420-3.00113-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
171 Chehab M, Hlubocky J, Olariu E, Bloom D, Nandalur K. Comprehensive magnetic resonance enterography of Crohn's disease in the pediatric population: technique, interpretation, and management. Curr Probl Diagn Radiol 2015;44:193-206. [PMID: 25155516 DOI: 10.1067/j.cpradiol.2014.07.003] [Reference Citation Analysis]
172 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn's disease. World J Gastroenterol 2011; 17(39): 4372-4381 [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
173 Lakatos PL, Altorjay I, Mándi Y, Lakatos L, Tumpek J, Kovacs A, Molnar T, Tulassay Z, Miheller P, Palatka K, Szamosi T, Fischer S, Papp J, Papp M; the Hungarian IBD Study Group. Interaction between seroreactivity to microbial antigens and genetics in Crohn’s disease: is there a role for defensins? Tissue Antigens 2008;71:552-9. [DOI: 10.1111/j.1399-0039.2008.01049.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
174 Gecse KB, Lakatos PL. Ulcerative proctitis: an update on the pharmacotherapy and management. Expert Opinion on Pharmacotherapy 2014;15:1565-73. [DOI: 10.1517/14656566.2014.920322] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
175 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, van Assche G. [Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. Rev Gastroenterol Mex 2014;79:263-89. [PMID: 25487134 DOI: 10.1016/j.rgmx.2014.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
176 Gao Y, Bai D, Zhao Y, Zhu Q, Zhou Y, Li Z, Lu N. LL202 ameliorates colitis against oxidative stress of macrophage by activation of the Nrf2/HO‐1 pathway. J Cell Physiol 2019;234:10625-39. [DOI: 10.1002/jcp.27739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
177 Ortuño Sahagún D, Márquez-Aguirre AL, Quintero-Fabián S, López-Roa RI, Rojas-Mayorquín AE. Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases. PPAR Res 2012;2012:318613. [PMID: 23251142 DOI: 10.1155/2012/318613] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
178 Vida Pérez L, Gómez Camacho F, García Sánchez V, Iglesias Flores EM, Castillo Molina L, Cerezo Ruiz A, Casáis Juanena L, De Dios Vega JF. [Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease]. Med Clin (Barc). 2009;132:331-335. [PMID: 19268981 DOI: 10.1016/j.medcli.2008.07.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
179 Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol. 2009;15:3504-3510. [PMID: 19630105 DOI: 10.3748/wjg.15.3504.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Brunson JL, Becker F, Stokes KY. The impact of primary and persistent cytomegalovirus infection on the progression of acute colitis in a murine model. Pathophysiology 2015;22:31-7. [PMID: 25511533 DOI: 10.1016/j.pathophys.2014.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
181 Meissner Y, Lamprecht A. Alternative drug delivery approaches for the therapy of inflammatory bowel disease. J Pharm Sci. 2008;97:2878-2891. [PMID: 17948914 DOI: 10.1002/jps.21216] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
182 Nagalingam NA, Robinson CJ, Bergin IL, Eaton KA, Huffnagle GB, Young VB. The effects of intestinal microbial community structure on disease manifestation in IL-10-/- mice infected with Helicobacter hepaticus. Microbiome. 2013;1:15. [PMID: 24450737 DOI: 10.1186/2049-2618-1-15] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
183 Kozłowska KA, Bączyk G, Krokowicz P. Quality of life in patients with ulcerative colitis treated surgically. Prz Gastroenterol 2014;9:220-6. [PMID: 25276253 DOI: 10.5114/pg.2014.45104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
184 Szamosi T, Lakatos PL, Szilvasi A, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szabo O, Satori A. The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patients. Dig Dis Sci. 2009;54:351-359. [PMID: 18716880 DOI: 10.1007/s10620-008-0351-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
185 Damas OM, Jahann DA, Reznik R, McCauley JL, Tamariz L, Deshpande AR, Abreu MT, Sussman DA. Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol. 2013;108:231-239. [PMID: 23247580 DOI: 10.1038/ajg.2012.393] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
186 Nørgård BM, Nielsen J, Fonager K, Kjeldsen J, Jacobsen BA, Qvist N. The incidence of ulcerative colitis (1995-2011) and Crohn's disease (1995-2012) - based on nationwide Danish registry data. J Crohns Colitis 2014;8:1274-80. [PMID: 24675473 DOI: 10.1016/j.crohns.2014.03.006] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
187 Schoultz M, Macaden L, Watson AJ. Co-designing inflammatory bowel disease (Ibd) services in Scotland: findings from a nationwide survey. BMC Health Serv Res 2016;16:231. [PMID: 27391695 DOI: 10.1186/s12913-016-1490-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
188 Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012;11:754-65. [PMID: 22387972 DOI: 10.1016/j.autrev.2012.02.001] [Cited by in Crossref: 213] [Cited by in F6Publishing: 198] [Article Influence: 23.7] [Reference Citation Analysis]
189 Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol. 2010;16:2591-2599. [PMID: 20518079 DOI: 10.3748/wjg.v16.i21.2591.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 Zhang Z, Li C, Zhao X, Lv C, He Q, Lei S, Guo Y, Zhi F. Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis Sci 2012;57:2944-54. [PMID: 22669207 DOI: 10.1007/s10620-012-2244-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
191 Schneider M. Dextran Sodium Sulfate-Induced Murine Inflammatory Colitis Model. In: Allen IC, editor. Mouse Models of Innate Immunity. Totowa: Humana Press; 2013. pp. 189-95. [DOI: 10.1007/978-1-62703-481-4_21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
192 Oliva-hemker M, Escher J, Moore D, Dubinksy M, Hildebrand H, Koda Y, Murch S, Sandhu B, Seo J, Tanzi M, Warner B. Refractory Inflammatory Bowel Disease in Children. Journal of Pediatric Gastroenterology & Nutrition 2008;47:266-72. [DOI: 10.1097/mpg.0b013e318181b48c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 刘晨晨, 张振玉. 巨细胞病毒感染与炎症性肠病的关系. 世界华人消化杂志 2015; 23(11): 1784-1790 [DOI: 10.11569/wcjd.v23.i11.1784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Qin X. What caused the extra high incidence of inflammatory bowel disease in the industrialized countries in the West: lack of some nutrients or increased intake of some harmful agents? Inflamm Bowel Dis. 2009;15:319. [PMID: 18668675 DOI: 10.1002/ibd.20606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Siddique I, Alazmi W, Al-ali J, Longenecker JC, Al-fadli A, Hasan F, Memon A. Demography and clinical course of ulcerative colitis in Arabs – a study based on the Montreal classification. Scandinavian Journal of Gastroenterology 2014;49:1432-40. [DOI: 10.3109/00365521.2014.966318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
196 Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis. 2009;15:365-374. [PMID: 18972554 DOI: 10.1002/ibd.20778] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
197 Bowcutt R, Malter LB, Chen LA, Wolff MJ, Robertson I, Rifkin DB, Poles M, Cho I, Loke P. Isolation and cytokine analysis of lamina propria lymphocytes from mucosal biopsies of the human colon. J Immunol Methods 2015;421:27-35. [PMID: 25769417 DOI: 10.1016/j.jim.2015.02.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
198 Romier B, Van De Walle J, During A, Larondelle Y, Schneider YJ. Modulation of signalling nuclear factor-kappaB activation pathway by polyphenols in human intestinal Caco-2 cells. Br J Nutr 2008;100:542-51. [PMID: 18377686 DOI: 10.1017/S0007114508966666] [Cited by in Crossref: 108] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
199 Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: How to improve it? World J Gastroenterol 2009; 15(34): 4234-4239 [PMID: 19750566 DOI: 10.3748/wjg.15.4234] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
200 Kostadinova FI, Baba T, Ishida Y, Kondo T, Popivanova BK, Mukaida N. Crucial involvement of the CX3CR1-CX3CL1 axis in dextran sulfate sodium-mediated acute colitis in mice. J Leukoc Biol. 2010;88:133-143. [PMID: 20335311 DOI: 10.1189/jlb.1109768] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
201 Poliska S, Penyige A, Lakatos PL, Papp M, Palatka K, Lakatos L, Molnar T, Nagy L; Hungarian IBD Study Group. Association of peroxisome proliferator-activated receptor gamma polymorphisms with inflammatory bowel disease in a Hungarian cohort. Inflamm Bowel Dis 2012;18:472-9. [PMID: 21710534 DOI: 10.1002/ibd.21798] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
202 Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44:1199-1212. [PMID: 27714831 DOI: 10.1111/apt.13813] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 20.4] [Reference Citation Analysis]
203 Zargar A, Gooraji SA, Keshavarzi B, Haji Aghamohammadi AA. Effect of Irritable Bowel Syndrome on Sleep Quality and Quality of Life of Inflammatory Bowel Disease in Clinical Remission. Int J Prev Med 2019;10:10. [PMID: 30774844 DOI: 10.4103/ijpvm.IJPVM_364_17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
204 Sloan SR, Andrzejewski C Jr, Aqui NA, Kiss JE, Krause PJ, Park YA. Role of therapeutic apheresis in infectious and inflammatory diseases: Current knowledge and unanswered questions. J Clin Apher 2015;30:259-64. [PMID: 25351167 DOI: 10.1002/jca.21370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
205 Lakatos PL, Kiss LS, Miheller P. Nutritional influences in selected gastrointestinal diseases. Dig Dis. 2011;29:154-165. [PMID: 21734379 DOI: 10.1159/000323878] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
206 Kanaan Z, Rai SN, Eichenberger MR, Barnes C, Dworkin AM, Weller C, Cohen E, Roberts H, Keskey B, Petras RE, Crawford NP, Galandiuk S. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat. 2012;33:551-560. [PMID: 22241525 DOI: 10.1002/humu.22021] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 9.2] [Reference Citation Analysis]
207 Crandall W, Kappelman MD, Colletti RB, Leibowitz I, Grunow JE, Ali S, Baron HI, Berman JH, Boyle B, Cohen S. ImproveCareNow: The development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis. 2011;17:450-457. [PMID: 20602466 DOI: 10.1002/ibd.21394] [Cited by in Crossref: 117] [Cited by in F6Publishing: 109] [Article Influence: 11.7] [Reference Citation Analysis]
208 Lü M, Xia B, Ge L, Li Y, Zhao J, Chen F, Zhou F, Zhang X, Tan J. Role of major histocompatibility complex class I-related molecules A*A5.1 allele in ulcerative colitis in Chinese patients. Immunology. 2009;128:e230-e236. [PMID: 19016911 DOI: 10.1111/j.1365-2567.2008.02953.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
209 Gonçalves P, Araújo JR, Di Santo JP. A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:558-72. [PMID: 29462379 DOI: 10.1093/ibd/izx029] [Cited by in Crossref: 111] [Cited by in F6Publishing: 106] [Article Influence: 55.5] [Reference Citation Analysis]
210 D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. A phase II study of laquinimod in Crohn's disease. Gut 2015;64:1227-35. [PMID: 25281416 DOI: 10.1136/gutjnl-2014-307118] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
211 Givvimani S, Munjal C, Narayanan N, Aqil F, Tyagi G, Metreveli N, Tyagi SC. Hyperhomocysteinemia decreases intestinal motility leading to constipation. Am J Physiol Gastrointest Liver Physiol 2012;303:G281-90. [PMID: 22595990 DOI: 10.1152/ajpgi.00423.2011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
212 Cabré E, Mañosa M, Gassull MA. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. Br J Nutr 2012;107 Suppl 2:S240-52. [PMID: 22591898 DOI: 10.1017/S0007114512001626] [Cited by in Crossref: 81] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
213 Lakatos PL, Szamosi T, Szilvasi A, Molnar E, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Tulassay Z, Miheller P, Papp J, Tordai A, Andrikovics H; Hungarian IBD Study Group. ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients. Dig Liver Dis 2008;40:867-73. [PMID: 18499543 DOI: 10.1016/j.dld.2008.03.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 48] [Article Influence: 2.6] [Reference Citation Analysis]
214 Chen Y, Zheng J, Qu C, Xiao Y, Li F, Jin Q, Li H, Meng F, Jin G, Jin D. Inonotus obliquus polysaccharide ameliorates dextran sulphate sodium induced colitis involving modulation of Th1/Th2 and Th17/Treg balance. Artificial Cells, Nanomedicine, and Biotechnology 2019;47:757-66. [DOI: 10.1080/21691401.2019.1577877] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
215 Lakatos L, Kiss LS, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Lakatos PL. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis. 2011;17:2558-2565. [PMID: 22072315 DOI: 10.1002/ibd.21607] [Cited by in Crossref: 106] [Cited by in F6Publishing: 96] [Article Influence: 10.6] [Reference Citation Analysis]
216 Lee EJ, Kim TO, Song GA, Lee JH, Kim HW, Jee SR, Park SJ, Kim HJ, Park JH. Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam. Intest Res 2016;14:30-6. [PMID: 26884732 DOI: 10.5217/ir.2016.14.1.30] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
217 Saha P, Manoharan P, Arthur S, Sundaram S, Kekuda R, Sundaram U. Molecular mechanism of regulation of villus cell Na-K-ATPase in the chronically inflamed mammalian small intestine. Biochim Biophys Acta 2015;1848:702-11. [PMID: 25462166 DOI: 10.1016/j.bbamem.2014.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
218 Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665-681. [PMID: 18047543 DOI: 10.1111/j.1572-0241.2007.01652.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 94] [Article Influence: 6.2] [Reference Citation Analysis]
219 Huang Y, Zhou J, Qu C, Dou Y, Huang Q, Lin Z, Xian Y, Xie J, Xie Y, Lai X, Su Z. Anti-inflammatory effects of Brucea javanica oil emulsion by suppressing NF-κB activation on dextran sulfate sodium-induced ulcerative colitis in mice. Journal of Ethnopharmacology 2017;198:389-98. [DOI: 10.1016/j.jep.2017.01.042] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
220 AlQasrawi D, Abdelli LS, Naser SA. Mystery Solved: Why Smoke Extract Worsens Disease in Smokers with Crohn's Disease and Not Ulcerative Colitis? Gut MAP! Microorganisms 2020;8:E666. [PMID: 32370298 DOI: 10.3390/microorganisms8050666] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
221 Ruyssers NE, De Winter BY, De Man JG, Loukas A, Herman AG, Pelckmans PA, Moreels TG. Worms and the treatment of inflammatory bowel disease: are molecules the answer? Clin Dev Immunol 2008;2008:567314. [PMID: 18509490 DOI: 10.1155/2008/567314] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
222 Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release. 2012;161:235-246. [PMID: 22306429 DOI: 10.1016/j.jconrel.2012.01.028] [Cited by in Crossref: 141] [Cited by in F6Publishing: 128] [Article Influence: 15.7] [Reference Citation Analysis]
223 Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J, Lakatos L. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease. World J Gastroenterol 2009; 15(28): 3504-3510 [PMID: 19630105 DOI: 10.3748/wjg.15.3504] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 81] [Article Influence: 6.3] [Reference Citation Analysis]
224 Benight NM, Stoll B, Marini JC, Burrin DG. Preventative oral methylthioadenosine is anti-inflammatory and reduces DSS-induced colitis in mice. Am J Physiol Gastrointest Liver Physiol 2012;303:G71-82. [PMID: 22556140 DOI: 10.1152/ajpgi.00549.2011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
225 Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007;13:6134-9. [PMID: 18069751 DOI: 10.3748/wjg.v13.i46.6134] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
226 Jianzhong H. The genetic predisposition and the interplay of host genetics and gut microbiome in Crohn disease. Clin Lab Med 2014;34:763-70. [PMID: 25439275 DOI: 10.1016/j.cll.2014.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
227 Meggyesi N, Kiss LS, Koszarska M, Bortlik M, Duricova D, Lakatos L, Molnar T, Leniček M, Vítek L, Altorjay I, Papp M, Tulassay Z, Miheller P, Papp J, Tordai A, Andrikovics H, Lukas M, Lakatos PL. NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients. World J Gastroenterol 2010; 16(41): 5233-5240 [PMID: 21049557 DOI: 10.3748/wjg.v16.i41.5233] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
228 de Groof EJ, Rossen NG, van Rhijn BD, Karregat EP, Boonstra K, Hageman I, Bennebroek Evertsz F, Kingma PJ, Naber AH, van den Brande JH, Mallant-hent RC, Mundt MW, D’haens GR, Ponsioen CY. Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands: . European Journal of Gastroenterology & Hepatology 2016;28:1065-72. [DOI: 10.1097/meg.0000000000000660] [Cited by in Crossref: 26] [Cited by in F6Publishing: 6] [Article Influence: 5.2] [Reference Citation Analysis]
229 Földes A, Kádár K, Kerémi B, Zsembery Á, Gyires K, S Zádori Z, Varga G. Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage. Curr Neuropharmacol 2016;14:914-34. [PMID: 26791480 DOI: 10.2174/1570159x14666160121115210] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
230 Lu ZK, Chen ZR, Zhu JY, Xu Y, Hua X. Analysis of the association of single nucleotide polymorphisms of interleukin-23 receptor (IL-23R) and inflammatory bowel disease in a Chinese Han cohort. Oncotarget 2016;7:67851-6. [PMID: 27765927 DOI: 10.18632/oncotarget.12296] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
231 Wang YF, Ou-yang Q, Xia B, Liu LN, Gu F, Zhou KF, Mei Q, Shi RH, Ran ZH, Wang XD, Hu PJ, Wu KC, Liu XG, Miao YL, Han Y, Wu XP, He GB, Zhong J, Liu GJ. Multicenter case-control study of the risk factors for ulcerative colitis in China. World J Gastroenterol 2013; 19(11): 1827-1833 [PMID: 23555172 DOI: 10.3748/wjg.v19.i11.1827] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
232 Sung JJ, Kamm MA, Marteau P. Asian perspectives in the management of inflammatory bowel disease: Findings from a recent survey. J Gastroenterol Hepatol. 2010;25:183-193. [PMID: 19929931 DOI: 10.1111/j.1440-1746.2009.06024.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
233 Swaroop PP. Inflammatory bowel diseases in the elderly. Clin Geriatr Med. 2007;23:809-821, vi. [PMID: 17923339 DOI: 10.1016/j.cger.2007.06.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
234 Azevedo LF, Magro F, Portela F, Lago P, Deus J, Cotter J, Cremers I, Vieira A, Peixe P, Caldeira P, Lopes H, Gonçalves R, Reis J, Cravo M, Barros L, Ministro P, Lurdes M, Duarte A, Campos M, Carvalho L, Costa-pereira A. Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach: PREVALENCE OF IBD IN PORTUGAL-A PHARMACO-EPIDEMIOLOGICAL APPROACH. Pharmacoepidem Drug Safe 2010;19:499-510. [DOI: 10.1002/pds.1930] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
235 Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp M. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn’s disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010;22:872-879. [PMID: 19648821 DOI: 10.1097/meg.0b013e32833036d9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
236 Böhm SK, Kruis W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin Exp Gastroenterol 2014;7:369-83. [PMID: 25285021 DOI: 10.2147/CEG.S35691] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
237 Bauché D, Joyce-Shaikh B, Jain R, Grein J, Ku KS, Blumenschein WM, Ganal-Vonarburg SC, Wilson DC, McClanahan TK, Malefyt RW, Macpherson AJ, Annamalai L, Yearley JH, Cua DJ. LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis. Immunity 2018;49:342-352.e5. [PMID: 30097293 DOI: 10.1016/j.immuni.2018.07.007] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 19.7] [Reference Citation Analysis]
238 Zheng B, van Bergenhenegouwen J, Overbeek S, van de Kant HJ, Garssen J, Folkerts G, Vos P, Morgan ME, Kraneveld AD. Bifidobacterium breve attenuates murine dextran sodium sulfate-induced colitis and increases regulatory T cell responses. PLoS One 2014;9:e95441. [PMID: 24787575 DOI: 10.1371/journal.pone.0095441] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
239 Schwarz J, Sýkora J, Cvalínová D, Pomahačová R, Klečková J, Kryl M, Včelák P. Inflammatory bowel disease incidence in Czech children: A regional prospective study, 2000-2015. World J Gastroenterol 2017; 23(22): 4090-4101 [PMID: 28652662 DOI: 10.3748/wjg.v23.i22.4090] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
240 Andújar I, Ríos JL, Giner RM, Miguel Cerdá J, Recio Mdel C. Beneficial effect of shikonin on experimental colitis induced by dextran sulfate sodium in BALB/c mice. Evid Based Complement Alternat Med 2012;2012:271606. [PMID: 23346196 DOI: 10.1155/2012/271606] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
241 Valer P, Algaba A, Santos D, Fuentes ME, Nieto E, Gisbert JP, López P, Quintanilla E, García-alonso FJ, Guerra I, Páez Á, Bermejo F. Evaluation of the Quality of Semen and Sexual Function in Men with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:1144-53. [DOI: 10.1097/mib.0000000000001081] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 4.3] [Reference Citation Analysis]
242 Cars T, Wettermark B, Löfberg R, Eriksson I, Sundström J, Lördal M. Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease. J Crohns Colitis 2016;10:556-65. [PMID: 26733406 DOI: 10.1093/ecco-jcc/jjv243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
243 Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis. 2008;2:1-23. [PMID: 21172194 DOI: 10.1016/j.crohns.2007.11.001] [Cited by in Crossref: 353] [Cited by in F6Publishing: 324] [Article Influence: 27.2] [Reference Citation Analysis]
244 Cai X, Liu Y, Zhou X, Navaneethan U, Shen B, Guo B. An LC-ESI-MS method for the quantitative analysis of bile acids composition in fecal materials: Quantitative analysis of bile acids in fecal materials. Biomed Chromatogr 2012;26:101-8. [DOI: 10.1002/bmc.1633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
245 Jussila A, Virta LJ, Kautiainen H, Rekiaro M, Nieminen U, Färkkilä MA. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis. 2012;18:555-561. [PMID: 21425214 DOI: 10.1002/ibd.21695] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
246 Zhang H, Shahbazi M, Almeida PV, Santos HA. Mucus as a Barrier for Biopharmaceuticals and Drug Delivery Systems. In: das Neves J, Sarmento B, editors. Mucosal Delivery of Biopharmaceuticals. Boston: Springer US; 2014. pp. 59-97. [DOI: 10.1007/978-1-4614-9524-6_3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
247 Pacheco R, Contreras F, Zouali M. The dopaminergic system in autoimmune diseases. Front Immunol. 2014;5:117. [PMID: 24711809 DOI: 10.3389/fimmu.2014.00117] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 12.4] [Reference Citation Analysis]
248 Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012;5:7-18. [PMID: 22089028 DOI: 10.1038/mi.2011.55] [Cited by in Crossref: 151] [Cited by in F6Publishing: 157] [Article Influence: 15.1] [Reference Citation Analysis]
249 Kang SJ, Kim JM, Koh SJ, Kim SH, Im JP, Jung HC, Kim JS. The guggulsterone derivative GG-52 inhibits NF-κB signaling in bone marrow-derived dendritic cells and attenuates colitis in IL-10 knockout mice. Life Sci. 2013;92:1064-1071. [PMID: 23603141 DOI: 10.1016/j.lfs.2013.04.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
250 Pehlivaner Kara MO, Ekenseair AK. In situ spray deposition of cell-loaded, thermally and chemically gelling hydrogel coatings for tissue regeneration: IN SITU SPRAY DEPOSITION OF HYDROGEL COATINGS FOR TISSUE REGENERATION. J Biomed Mater Res 2016;104:2383-93. [DOI: 10.1002/jbm.a.35774] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
251 Huang X, Lv B, Jin H, Zhang S. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis. Eur J Clin Pharmacol 2011;67:759-66. [DOI: 10.1007/s00228-011-1079-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
252 Chang CW, Tu CH, Chou JW, Huang TY, Hsu WH, Wang YP, Chen CC, Chung CS, Lin CP, Lin WC, Tai CM, Wang HY, Chen MJ. Endoscopic management of strictures in patients with Crohn's disease - A multi-center experience in Taiwan. J Formos Med Assoc 2020;119:1500-5. [PMID: 31917065 DOI: 10.1016/j.jfma.2019.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
253 Aubry C, Michon C, Chain F, Chvatchenko Y, Goffin L, Zimmerli SC, Leguin S, Langella P, Bermudez-Humaran L, Chatel JM. Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model. Microb Cell Fact 2015;14:176. [PMID: 26546058 DOI: 10.1186/s12934-015-0367-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
254 Heiman ML, Greenway FL. A healthy gastrointestinal microbiome is dependent on dietary diversity. Mol Metab. 2016;5:317-320. [PMID: 27110483 DOI: 10.1016/j.molmet.2016.02.005] [Cited by in Crossref: 121] [Cited by in F6Publishing: 103] [Article Influence: 24.2] [Reference Citation Analysis]
255 Viladomiu M, Hontecillas R, Bassaganya-Riera J. Modulation of inflammation and immunity by dietary conjugated linoleic acid. Eur J Pharmacol 2016;785:87-95. [PMID: 25987426 DOI: 10.1016/j.ejphar.2015.03.095] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 13.5] [Reference Citation Analysis]
256 Zhao J, Cui MY, Chan T, Mao R, Luo Y, Barua I, Chen M, Li ZP, Feng ST. Evaluation of intestinal tuberculosis by multi-slice computed tomography enterography. BMC Infect Dis 2015;15:577. [PMID: 26695641 DOI: 10.1186/s12879-015-1325-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
257 Sjöberg D, Holmström T, Larsson M, Nielsen AL, Holmquist L, Ekbom A, Rönnblom A. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005-2009 - results from the IBD cohort of the Uppsala Region (ICURE). J Crohns Colitis 2013;7:e351-7. [PMID: 23491313 DOI: 10.1016/j.crohns.2013.02.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
258 Werner T, Haller D. Intestinal epithelial cell signalling and chronic inflammation: From the proteome to specific molecular mechanisms. Mutat Res. 2007;622:42-57. [PMID: 17628614 DOI: 10.1016/j.mrfmmm.2007.05.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
259 Ciaccio EJ, Bhagat G, Lewis SK, Green PH. Trends in celiac disease research. Comput Biol Med. 2015;65:369-378. [PMID: 26095989 DOI: 10.1016/j.compbiomed.2015.05.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]